Parallel increase in community use of fosfomycin and resistance to fosfomycin in extended-spectrum  -lactamase (ESBL)-producing Escherichia coli

Prevalence of Fosfomycin Resistance among CTX-M-Producing Escherichia coli Clinical Isolates in Japan and Identification of Novel Plasmid-Mediated Fosfomycin-Modifying Enzymes

(2010) J.-i. Wachino et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Extended-spectrum β-lactamase producing Escherichia coli: changing epidemiology and clinical impact

(2010) Jesús Oteo et al.   CURRENT OPINION IN INFECTIOUS DISEASES

Fosfomycin versus other antibiotics for the treatment of cystitis: a meta-analysis of randomized controlled trials

(2010) Matthew E. Falagas et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

CTX-M-15-producing urinary Escherichia coli O25b-ST131-phylogroup B2 has acquired resistance to fosfomycin

(2009) J. Oteo et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Fosfomycin for the treatment of multidrug-resistant, including extended-spectrum β-lactamase producing, Enterobacteriaceae infections: a systematic review

(2009) Matthew E Falagas et al.   LANCET INFECTIOUS DISEASES

Fosfomycin tromethamine as second agent for the treatment of acute, uncomplicated urinary tract infections in adult female patients in The Netherlands?

(2008) B. J. Knottnerus et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

The CTX-M-15-producing Escherichia coli diffusing clone belongs to a highly virulent B2 phylogenetic subgroup

(2008) Olivier Clermont et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY